Skip to main content
Top
Published in: BMC Immunology 1/2021

Open Access 01-12-2021 | ANCA-Associated Vasculitis | Research article

Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment

Authors: Linlin Cheng, Yang Li, Ziyan Wu, Liubing Li, Chenxi Liu, Jianhua Liu, Jiayu Dai, Wenjie Zheng, Fengchun Zhang, Liujun Tang, Xiaobo Yu, Yongzhe Li

Published in: BMC Immunology | Issue 1/2021

Login to get access

Abstract

Background

Behcet’s disease (BD) is a relapsing systemic vascular autoimmune/inflammatory disease. Despite much effort to investigate BD, there are virtually no unique laboratory markers identified to help in the diagnosis of BD, and the pathogenesis is largely unknown. The aim of this work is to explore interactions between different clinical variables by correlation analysis to determine associations between the functional linkages of different paired variables and potential diagnostic biomarkers of BD.

Methods

We measured the immunoglobulin proteome (IgG, IgG1–4, IgA, IgA1–2) and 29 clinical variables in 66 healthy controls and 63 patients with BD. We performed a comprehensive clinical variable linkage analysis and defined the physiological, pathological and pharmacological linkages based on the correlations of all variables in healthy controls and BD patients without and with immunomodulatory therapy. We further calculated relative changes between variables derived from comprehensive linkage analysis for better indications in the clinic. The potential indicators were validated in a validation set with 76 patients with BD, 30 healthy controls, 18 patients with Takayasu arteritis and 18 patients with ANCA-associated vasculitis.

Results

In this study, the variables identified were found to act in synergy rather than alone in BD patients under physiological, pathological and pharmacological conditions. Immunity and inflammation can be suppressed by corticosteroids and immunosuppressants, and integrative analysis of granulocytes, platelets and related variables is likely to provide a more comprehensive understanding of disease activity, thrombotic potential and ultimately potential tissue damage. We determined that total protein/mean corpuscular hemoglobin and total protein/mean corpuscular hemoglobin levels, total protein/mean corpuscular volume, and plateletcrit/monocyte counts were significantly increased in BD compared with controls (P < 0.05, in both the discovery and validation sets), which helped in distinguishing BD patients from healthy and vasculitis controls. Chronic anemia in BD combined with increased total protein contributed to higher levels of these biomarkers, and the interactions between platelets and monocytes may be linked to vascular involvement.

Conclusions

All these results demonstrate the utility of our approach in elucidating the pathogenesis and in identifying novel biomarkers for autoimmune diseases in the future.
Appendix
Available only for authorised users
Literature
1.
go back to reference Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi AB. Behcet's disease: from east to west. Clin Rheumatol. 2010;29:823–33.PubMedCrossRef Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi AB. Behcet's disease: from east to west. Clin Rheumatol. 2010;29:823–33.PubMedCrossRef
2.
go back to reference Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.PubMedCrossRef Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.PubMedCrossRef
3.
go back to reference Direskeneli H, Saruhan-Direskeneli G. Disease mechanisms. In: Yazıcı Y, Yazıcı H, editors. Behçet’s Syndrome. New York, NY: Springer New York; 2010. p. 243–64.CrossRef Direskeneli H, Saruhan-Direskeneli G. Disease mechanisms. In: Yazıcı Y, Yazıcı H, editors. Behçet’s Syndrome. New York, NY: Springer New York; 2010. p. 243–64.CrossRef
4.
go back to reference Djaballah-Ider F, Djaballah A, Djeraba Z, Chaib S, Touil-Boukoffa C. Auto-immunity profile evaluation during different clinical manifestations of Behcet disease in Algerian patients: effect of corticosteroid treatment. Inflammopharmacology. 2019;27:1113–22.PubMedCrossRef Djaballah-Ider F, Djaballah A, Djeraba Z, Chaib S, Touil-Boukoffa C. Auto-immunity profile evaluation during different clinical manifestations of Behcet disease in Algerian patients: effect of corticosteroid treatment. Inflammopharmacology. 2019;27:1113–22.PubMedCrossRef
5.
go back to reference Cho SB, Zheng Z, Ahn KJ, Choi MJ, Cho S, Kim DY, Lee HS, Bang D. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behcet disease. Br J Dermatol. 2013;168:977–83.PubMedCrossRef Cho SB, Zheng Z, Ahn KJ, Choi MJ, Cho S, Kim DY, Lee HS, Bang D. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behcet disease. Br J Dermatol. 2013;168:977–83.PubMedCrossRef
6.
go back to reference Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42:157–76 ix-x.CrossRef Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42:157–76 ix-x.CrossRef
7.
go back to reference Djaballah-Ider F, Djeraba Z, Chemli M, Dammene-Debbihe N, Lounis D, Belguendouz H, Medour Y, Chaib S, Touil-Boukoffa C. Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behcet's disease. Inflammopharmacology. 2018;26:725–35.PubMedCrossRef Djaballah-Ider F, Djeraba Z, Chemli M, Dammene-Debbihe N, Lounis D, Belguendouz H, Medour Y, Chaib S, Touil-Boukoffa C. Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behcet's disease. Inflammopharmacology. 2018;26:725–35.PubMedCrossRef
8.
go back to reference Bohler C, Radner H, Smolen JS, Aletaha D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis. 2013;72:241–4.PubMedCrossRef Bohler C, Radner H, Smolen JS, Aletaha D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis. 2013;72:241–4.PubMedCrossRef
9.
go back to reference Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol. 2008;27:373–5.PubMedCrossRef Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol. 2008;27:373–5.PubMedCrossRef
10.
go back to reference Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI. Immunotherapy of systemic sclerosis. Human Vaccines & Immunotherapeutics. 2018;14:2559–67. Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI. Immunotherapy of systemic sclerosis. Human Vaccines & Immunotherapeutics. 2018;14:2559–67.
11.
go back to reference Price ND, Magis AT, Earls JC, Glusman G, Levy R, Lausted C, Mcdonald DT, Kusebauch U, Moss CL, Zhou Y, Qin S, Moritz RL, Brogaard K, Omenn GS, Lovejoy JC, Hood L. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017;35:747–56.PubMedPubMedCentralCrossRef Price ND, Magis AT, Earls JC, Glusman G, Levy R, Lausted C, Mcdonald DT, Kusebauch U, Moss CL, Zhou Y, Qin S, Moritz RL, Brogaard K, Omenn GS, Lovejoy JC, Hood L. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017;35:747–56.PubMedPubMedCentralCrossRef
12.
go back to reference Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsboll T, Junker A, Sachs S, Stemmer K, Muller TD, Tschop MH, Hofmann SM, Mann M. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol. 2019;15:e8793.PubMedPubMedCentralCrossRef Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsboll T, Junker A, Sachs S, Stemmer K, Muller TD, Tschop MH, Hofmann SM, Mann M. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol. 2019;15:e8793.PubMedPubMedCentralCrossRef
13.
go back to reference Geyer PE, Wewer Albrechtsen NJ, Tyanova S, Grassl N, Iepsen EW, Lundgren J, Madsbad S, Holst JJ, Torekov SS, Mann M. Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol. 2016;12:901.PubMedPubMedCentralCrossRef Geyer PE, Wewer Albrechtsen NJ, Tyanova S, Grassl N, Iepsen EW, Lundgren J, Madsbad S, Holst JJ, Torekov SS, Mann M. Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol. 2016;12:901.PubMedPubMedCentralCrossRef
14.
go back to reference Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y, Yao D, Deng H, Wang D, Sun Y, Chang C, Zhang X, Dai J, Yue L, Zhang Q, Cai X, Zhu Y, Duan H, Liu Y, Li D, Zhu Y, Radstake T, Balak DMW, Xu D, Guo T, Lu C, Yu X. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019;9:2475–88.PubMedPubMedCentralCrossRef Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y, Yao D, Deng H, Wang D, Sun Y, Chang C, Zhang X, Dai J, Yue L, Zhang Q, Cai X, Zhu Y, Duan H, Liu Y, Li D, Zhu Y, Radstake T, Balak DMW, Xu D, Guo T, Lu C, Yu X. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019;9:2475–88.PubMedPubMedCentralCrossRef
15.
go back to reference Koivula RW, Forgie IM, Kurbasic A, Vinuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, Siloaho M, Allin KH, Brage S, Brorsson CA, Dawed AY, De Masi F, Groves CJ, Kokkola T, Mahajan A, Perry MH, Rauh SP, Ridderstrale M, Teare HJA, Thomas EL, Tura A, Vestergaard H, White T, Adamski J, Bell JD, Beulens JW, Brunak S, Dermitzakis ET, Froguel P, Frost G, Gupta R, Hansen T, Hattersley A, Jablonka B, Kaye J, Laakso M, Mcdonald TJ, Pedersen O, Schwenk JM, Pavo I, Mari A, Mccarthy MI, Ruetten H, Walker M, Pearson E, Franks PW. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia. 2019;62:1601–15.PubMedPubMedCentralCrossRef Koivula RW, Forgie IM, Kurbasic A, Vinuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, Siloaho M, Allin KH, Brage S, Brorsson CA, Dawed AY, De Masi F, Groves CJ, Kokkola T, Mahajan A, Perry MH, Rauh SP, Ridderstrale M, Teare HJA, Thomas EL, Tura A, Vestergaard H, White T, Adamski J, Bell JD, Beulens JW, Brunak S, Dermitzakis ET, Froguel P, Frost G, Gupta R, Hansen T, Hattersley A, Jablonka B, Kaye J, Laakso M, Mcdonald TJ, Pedersen O, Schwenk JM, Pavo I, Mari A, Mccarthy MI, Ruetten H, Walker M, Pearson E, Franks PW. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia. 2019;62:1601–15.PubMedPubMedCentralCrossRef
16.
go back to reference Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335:1078–80. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335:1078–80.
17.
go back to reference Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS, Ali AA, Altenburg A, Arromdee E, Baltaci M, Bastos M, Benamour S, Ben Ghorbel I, Boyvat A, Carvalho L, Chen W, Ben-Chetrit E, Chams-Davatchi C, Correia JA, Crespo J, Dias C, Dong Y, Paixão-Duarte F, Elmuntaser K, Elonakov AV, Graña Gil J, Haghdoost A-A, Hayani RM, Houman H, Isayeva AR, Jamshidi AR, Kaklamanis P, Kumar A, Kyrgidis A, Madanat W, Nadji A, Namba K, Ohno S, Olivieri I, Vaz Patto J, Pipitone N, De Queiroz MV, Ramos F, Resende C, Rosa CM, Salvarani C, Serra MJ, Shahram F, Shams H, Sharquie KE, Sliti-Khanfir M, Tribolet De Abreu T, Vasconcelos C, Vedes J, Wechsler B, Cheng YK, Zhang Z, Ziaei N. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRef Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS, Ali AA, Altenburg A, Arromdee E, Baltaci M, Bastos M, Benamour S, Ben Ghorbel I, Boyvat A, Carvalho L, Chen W, Ben-Chetrit E, Chams-Davatchi C, Correia JA, Crespo J, Dias C, Dong Y, Paixão-Duarte F, Elmuntaser K, Elonakov AV, Graña Gil J, Haghdoost A-A, Hayani RM, Houman H, Isayeva AR, Jamshidi AR, Kaklamanis P, Kumar A, Kyrgidis A, Madanat W, Nadji A, Namba K, Ohno S, Olivieri I, Vaz Patto J, Pipitone N, De Queiroz MV, Ramos F, Resende C, Rosa CM, Salvarani C, Serra MJ, Shahram F, Shams H, Sharquie KE, Sliti-Khanfir M, Tribolet De Abreu T, Vasconcelos C, Vedes J, Wechsler B, Cheng YK, Zhang Z, Ziaei N. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRef
18.
go back to reference Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–34.PubMedCrossRef Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–34.PubMedCrossRef
19.
go back to reference Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef
20.
go back to reference Yu X, Wallstrom G, Magee DM, Qiu J, Mendoza DE, Wang J, Bian X, Graves M, Labaer J. Quantifying antibody binding on protein microarrays using microarray nonlinear calibration. Biotechniques. 2013;54:257–64.PubMedPubMedCentralCrossRef Yu X, Wallstrom G, Magee DM, Qiu J, Mendoza DE, Wang J, Bian X, Graves M, Labaer J. Quantifying antibody binding on protein microarrays using microarray nonlinear calibration. Biotechniques. 2013;54:257–64.PubMedPubMedCentralCrossRef
21.
go back to reference Bassyouni IH, Mohammed WHS, Taha FM, El Refai RM. Clinical significance of CCN2/connective tissue growth factor in Behcet's disease patients. Int J Rheum Dis. 2019;22:1459–65.PubMed Bassyouni IH, Mohammed WHS, Taha FM, El Refai RM. Clinical significance of CCN2/connective tissue growth factor in Behcet's disease patients. Int J Rheum Dis. 2019;22:1459–65.PubMed
22.
go back to reference Dong Z, Shi J, Dorhoi A, Zhang J, Soodeen-Lalloo AK, Tan W, Yin H, Sha W, Li W, Zheng R, Liu Z, Yang H, Qin L, Wang J, Huang X, Wu C, Kaufmann SHE, Feng Y. Hemostasis and lipoprotein indices signify exacerbated lung injury in TB with diabetes comorbidity. Chest. 2018;153:1187–200.PubMedCrossRef Dong Z, Shi J, Dorhoi A, Zhang J, Soodeen-Lalloo AK, Tan W, Yin H, Sha W, Li W, Zheng R, Liu Z, Yang H, Qin L, Wang J, Huang X, Wu C, Kaufmann SHE, Feng Y. Hemostasis and lipoprotein indices signify exacerbated lung injury in TB with diabetes comorbidity. Chest. 2018;153:1187–200.PubMedCrossRef
23.
go back to reference Erdogmus S, Kendi Celebi Z, Akturk S, Kumru G, Duman N, Ates K, Erturk S, Nergizoglu G, Kutlay S, Sengul S, Keven K. Profile of renal AA amyloidosis in older and younger individuals: a single-Centre experience. Amyloid. 2018;25:115–9.PubMedCrossRef Erdogmus S, Kendi Celebi Z, Akturk S, Kumru G, Duman N, Ates K, Erturk S, Nergizoglu G, Kutlay S, Sengul S, Keven K. Profile of renal AA amyloidosis in older and younger individuals: a single-Centre experience. Amyloid. 2018;25:115–9.PubMedCrossRef
24.
go back to reference Zheng W, Li G, Zhou M, Chen L, Tian X, Zhang F. Renal involvement in Chinese patients with Behcet's disease: a report of 16 cases. Int J Rheum Dis. 2015;18:892–7.PubMedCrossRef Zheng W, Li G, Zhou M, Chen L, Tian X, Zhang F. Renal involvement in Chinese patients with Behcet's disease: a report of 16 cases. Int J Rheum Dis. 2015;18:892–7.PubMedCrossRef
25.
go back to reference Karakochuk CD, Hess SY, Moorthy D, Namaste S, Parker ME, Rappaport AI, Wegmuller R, Dary O. Measurement and interpretation of hemoglobin concentration in clinical and field settings: a narrative review. Ann N Y Acad Sci. 2019;1450:126–46.PubMedCrossRef Karakochuk CD, Hess SY, Moorthy D, Namaste S, Parker ME, Rappaport AI, Wegmuller R, Dary O. Measurement and interpretation of hemoglobin concentration in clinical and field settings: a narrative review. Ann N Y Acad Sci. 2019;1450:126–46.PubMedCrossRef
26.
go back to reference Butta NV, Fernandez-Bello I, Lopez-Longo FJ, Jimenez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behcet disease. Semin Thromb Hemost. 2015;41:621–8.PubMedCrossRef Butta NV, Fernandez-Bello I, Lopez-Longo FJ, Jimenez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behcet disease. Semin Thromb Hemost. 2015;41:621–8.PubMedCrossRef
27.
go back to reference Stohl W, Kenol B, Kelly AJ, Ananth Correa A, Panush RS. Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases. Semin Arthritis Rheum. 2019;49:485–92. Stohl W, Kenol B, Kelly AJ, Ananth Correa A, Panush RS. Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases. Semin Arthritis Rheum. 2019;49:485–92.
28.
go back to reference Helliwell M, Coombes EJ, Moody BJ, Batstone GF, Robertson JC. Nutritional status in patients with rheumatoid arthritis. Ann Rheum Dis. 1984;43:386–90.PubMedPubMedCentralCrossRef Helliwell M, Coombes EJ, Moody BJ, Batstone GF, Robertson JC. Nutritional status in patients with rheumatoid arthritis. Ann Rheum Dis. 1984;43:386–90.PubMedPubMedCentralCrossRef
29.
go back to reference Cehreli R, Yavuzsen T, Ates H, Akman T, Ellidokuz H, Oztop I. Can inflammatory and nutritional serum markers predict chemotherapy outcomes and survival in advanced stage nonsmall cell lung Cancer patients? Biomed Res Int. 2019;2019:1648072.PubMedPubMedCentralCrossRef Cehreli R, Yavuzsen T, Ates H, Akman T, Ellidokuz H, Oztop I. Can inflammatory and nutritional serum markers predict chemotherapy outcomes and survival in advanced stage nonsmall cell lung Cancer patients? Biomed Res Int. 2019;2019:1648072.PubMedPubMedCentralCrossRef
30.
go back to reference Xu Z, Li Y, Yang X, Wang J, Li J. Early detection of coagulation abnormalities in patients at nutritional risk: the novel role of thromboelastography. Am Surg. 2014;80:81–6.PubMedCrossRef Xu Z, Li Y, Yang X, Wang J, Li J. Early detection of coagulation abnormalities in patients at nutritional risk: the novel role of thromboelastography. Am Surg. 2014;80:81–6.PubMedCrossRef
31.
go back to reference Wang W, Ren D, Wang CS, Li T, Yao HC. High sensitivity C-reactive protein to prealbumin ratio measurement as a marker of the prognosis in acute coronary syndrome. Sci Rep. 2019;9:11583.PubMedPubMedCentralCrossRef Wang W, Ren D, Wang CS, Li T, Yao HC. High sensitivity C-reactive protein to prealbumin ratio measurement as a marker of the prognosis in acute coronary syndrome. Sci Rep. 2019;9:11583.PubMedPubMedCentralCrossRef
32.
go back to reference Gulhar R, Jialal I. Physiology, acute phase reactants. StatPearls. Treasure Island (FL): StatPearls Publishing StatPearls Publishing LLC; 2019. Gulhar R, Jialal I. Physiology, acute phase reactants. StatPearls. Treasure Island (FL): StatPearls Publishing StatPearls Publishing LLC; 2019.
33.
go back to reference Niethammer D, KüMmerle-Deschner J, Dannecker GE. Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. Rheumatology. 1999;38:747–50.PubMedCrossRef Niethammer D, KüMmerle-Deschner J, Dannecker GE. Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. Rheumatology. 1999;38:747–50.PubMedCrossRef
34.
35.
go back to reference Borel JF. Immunosuppression. In: Delves PJ, editor. Encyclopedia of Immunology (Second Edition). Oxford: Elsevier; 1998. p. 1349–53.CrossRef Borel JF. Immunosuppression. In: Delves PJ, editor. Encyclopedia of Immunology (Second Edition). Oxford: Elsevier; 1998. p. 1349–53.CrossRef
36.
38.
go back to reference Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How glucocorticoids affect the neutrophil life. Int J Mol Sci. 2018;19:4090. Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How glucocorticoids affect the neutrophil life. Int J Mol Sci. 2018;19:4090.
39.
go back to reference Ince LM, Weber J, Scheiermann C. Control of leukocyte trafficking by stress-associated hormones. Front Immunol. 2018;9:3143.PubMedCrossRef Ince LM, Weber J, Scheiermann C. Control of leukocyte trafficking by stress-associated hormones. Front Immunol. 2018;9:3143.PubMedCrossRef
40.
go back to reference Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy. 1991;11:119s–25s.PubMed Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy. 1991;11:119s–25s.PubMed
41.
go back to reference Atas H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an Indicator of vascular thrombosis. Arch Iran Med. 2018;21:234–9.PubMed Atas H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an Indicator of vascular thrombosis. Arch Iran Med. 2018;21:234–9.PubMed
42.
go back to reference Schrottmaier WC, Mussbacher M, Salzmann M, Assinger A. Platelet-leukocyte interplay during vascular disease. Atherosclerosis. 2020;307:109–20.PubMedCrossRef Schrottmaier WC, Mussbacher M, Salzmann M, Assinger A. Platelet-leukocyte interplay during vascular disease. Atherosclerosis. 2020;307:109–20.PubMedCrossRef
43.
go back to reference Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behcet's disease with thrombotic tendency. Tohoku J Exp Med. 2010;221:119–23.PubMedCrossRef Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behcet's disease with thrombotic tendency. Tohoku J Exp Med. 2010;221:119–23.PubMedCrossRef
44.
go back to reference Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2003;14:335–6.PubMedCrossRef Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2003;14:335–6.PubMedCrossRef
45.
go back to reference Pamuk GE, Pamuk ON, Orüm H, Demir M, Turgut B, Cakir N. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study. Blood Coagul Fibrinolysis. 2010;21:113–7. Pamuk GE, Pamuk ON, Orüm H, Demir M, Turgut B, Cakir N. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study. Blood Coagul Fibrinolysis. 2010;21:113–7.
46.
go back to reference Demir Pektas S, Alatas E, Yilmaz N. Plateletcrit is potential biomarker for presence and severity of psoriasis vulgaris. Acta Medica Mediterranea. 2016; 32:1785. Demir Pektas S, Alatas E, Yilmaz N. Plateletcrit is potential biomarker for presence and severity of psoriasis vulgaris. Acta Medica Mediterranea. 2016; 32:1785.
47.
go back to reference Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet&rsquo;s disease as an Indicator of vascular thrombosis. Arch Iran Med. 2018;21:234–9.PubMed Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet&rsquo;s disease as an Indicator of vascular thrombosis. Arch Iran Med. 2018;21:234–9.PubMed
48.
go back to reference Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoğlu T. Monocyte activity in Behcet's disease. Br J Rheumatol. 1996;35:424–9.PubMedCrossRef Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoğlu T. Monocyte activity in Behcet's disease. Br J Rheumatol. 1996;35:424–9.PubMedCrossRef
50.
go back to reference Glezeva N, Gilmer JF, Watson CJ, Ledwidge M. A central role for monocyte-platelet interactions in heart failure. J Cardiovasc Pharmacol Ther. 2016;21:245–61.PubMedCrossRef Glezeva N, Gilmer JF, Watson CJ, Ledwidge M. A central role for monocyte-platelet interactions in heart failure. J Cardiovasc Pharmacol Ther. 2016;21:245–61.PubMedCrossRef
52.
go back to reference Ye J-F, Chen Y, Cai J-F, Shen Y, Zou J, Guan J-L. Incidence and risk factors for anemia among newly-diagnosed intestinal Behcet's disease patients. J Natl Med Assoc. 2019;111:407–12.PubMedCrossRef Ye J-F, Chen Y, Cai J-F, Shen Y, Zou J, Guan J-L. Incidence and risk factors for anemia among newly-diagnosed intestinal Behcet's disease patients. J Natl Med Assoc. 2019;111:407–12.PubMedCrossRef
53.
go back to reference Çiçek D, Kandi B, İlhan N, Bakar Dertlioğlu S, Demir B. Frequency of Anemia of Chronic Disease in Patients with Behcetís Disease. TURKDERM - Turkish Arch Dermatol Venereol. 2007;41:121–4. Çiçek D, Kandi B, İlhan N, Bakar Dertlioğlu S, Demir B. Frequency of Anemia of Chronic Disease in Patients with Behcetís Disease. TURKDERM - Turkish Arch Dermatol Venereol. 2007;41:121–4.
54.
go back to reference Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee CK, Yoo B. Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology. 2008;47:1228–30.PubMedCrossRef Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee CK, Yoo B. Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology. 2008;47:1228–30.PubMedCrossRef
55.
go back to reference Daglı M, Yilmaz S, Sivrikaya A, Celik G. The role of Prohepcidin and Hepcidin in Anemia associated with Behçet's disease. In: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi; 2012. p. 22. Daglı M, Yilmaz S, Sivrikaya A, Celik G. The role of Prohepcidin and Hepcidin in Anemia associated with Behçet's disease. In: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi; 2012. p. 22.
Metadata
Title
Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment
Authors
Linlin Cheng
Yang Li
Ziyan Wu
Liubing Li
Chenxi Liu
Jianhua Liu
Jiayu Dai
Wenjie Zheng
Fengchun Zhang
Liujun Tang
Xiaobo Yu
Yongzhe Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-021-00403-1

Other articles of this Issue 1/2021

BMC Immunology 1/2021 Go to the issue